Cardiorespiratory endurance, muscular flexibility and strength in first-episode schizophrenia patients: Use of a standardized fitness assessment

Early Intervention in Psychiatry

Volumn 6, Issue 2, 2012, Pages 185-190

  Gretchen Doorly, Denise ^a   Kite, Robin E ^a   Subotnik, Kenneth L ^a   Detore, Nicole R ^a   Ventura, Joseph ^a   Kurtz, Andrew S ^a   Nuechterlein, Keith H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Exercise test; Health; Measure; Physical fitness; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DISEASE DURATION; DRUG EXPOSURE; FEMALE; FIRST EPISODE SCHIZOPHRENIA; FITNESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE EXERCISE; MUSCLE STRENGTH; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; FEMALE; HUMANS; MALE; MUSCLE STRENGTH; MUSCLE, SKELETAL; PHYSICAL ENDURANCE; PHYSICAL FITNESS; SCHIZOPHRENIA; SMOKING; TIME FACTORS;

EID: 84859884426     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2011.00313.x     Document Type: Article

References (23)

1. Dixon LB, Wohlheiter K. Diabetes and mental illness: factors to keep in mind. Drug Benefit Trends 2003; 15: 33-44.
2. von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 2009; 438: 15-21.
3. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68: 4-7.
4. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B etal. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22: 547-62.
5. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224-35.
6. Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8.
7. Marder SR, Essock SM, Miller AL etal. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-49.
8. National Institute for Clinical Excellence Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: Author, 2003.
9. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
10. McCreadie RG, Kelly C, Connolly M etal. Dietary improvement in people with schizophrenia: randomised controlled trial. Br J Psychiatry 2005; 187: 346-51.
11. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137-41.
12. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101: 266-72.
13. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-9.
14. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007; 24: 481-5.
15. van Winkel R, De Hert M, Wampers M etal. Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69: 472-9.
16. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006; 51: 382-6.
17. Golding LA. YMCA Fitness Testing and Assessment Manual, 4th edn. Champaign, IL: Human Kinetics Publishers, 2000.
18. Rummel-Kluge C, Komossa K, Schwarz S etal. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-33.
19. Pate RR, Pratt M, Blair SN etal. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
20. U.S. Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
21. Bond DS, Phelan S, Leahey TM, Hill JO, Wing RR. Weight-loss maintenance in successful weight losers: surgical vs. non-surgical methods. Int J Obes 2008; 33: 173-80.
22. Maj M. Physical health care in persons with severe mental illness: a public health and ethical priority. World Psychiatry 2009; 8: 1-2.
23. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL etal. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1253-60.